{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:43:28Z","timestamp":1793882608300,"version":"4.7.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Jiangsu Commission of Health Medical Research Project","award":["Z2022019"],"award-info":[{"award-number":["Z2022019"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272671"],"award-info":[{"award-number":["82272671"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Cadre Health Research Project","award":["BJ21030"],"award-info":[{"award-number":["BJ21030"]}]},{"name":"Wu Jieping Fund","award":["320.6750.2021-2-73"],"award-info":[{"award-number":["320.6750.2021-2-73"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03723-3","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:01:03Z","timestamp":1741327263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Fei-Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"11","key":"3723_CR1","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3723_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1\u201321.","journal-title":"Gastric Cancer"},{"issue":"1","key":"3723_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2024;44(1):127\u201372.","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"3723_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439\u201349.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3723_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389\u201396.","journal-title":"Lancet Oncol"},{"issue":"17","key":"3723_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"X Paoletti","year":"2010","unstructured":"GASTRIC (Global Advanced\/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729\u201337.","journal-title":"JAMA"},{"issue":"4","key":"3723_CR7","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.5301\/tj.5000480","volume":"102","author":"M Di Bartolomeo","year":"2016","unstructured":"Di Bartolomeo M, Pietrantonio F, Rulli E, et al. Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. Tumori. 2016;102(4):e15\u201319.","journal-title":"Tumori"},{"issue":"18","key":"3723_CR8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"3723_CR9","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1038\/s41598-017-07750-3","volume":"7","author":"E Ter Veer","year":"2017","unstructured":"Ter Veer E, Ngai LL, van Valkenhoef G, et al. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. Sci Rep. 2017;7(1):7142.","journal-title":"Sci Rep"},{"issue":"1","key":"3723_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10120-015-0581-1","volume":"20","author":"K Shitara","year":"2017","unstructured":"Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20(1):175\u201381.","journal-title":"Gastric Cancer"},{"issue":"1","key":"3723_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s12885-018-4480-9","volume":"18","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao J, Song Y, et al. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018;18(1):547.","journal-title":"BMC Cancer"},{"issue":"3","key":"3723_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","volume":"32","author":"SH Park","year":"2021","unstructured":"Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32(3):368\u201374.","journal-title":"Ann Oncol"},{"issue":"12","key":"3723_CR13","doi-asserted-by":"publisher","first-page":"13031","DOI":"10.1002\/cam4.5977","volume":"12","author":"L Feng","year":"2023","unstructured":"Feng L, Shao L, Sun S, et al. Analysis of the efficacy and influencing factors of preoperative P-SOX neoadjuvant chemotherapy regimen for progressive gastric cancer-construction of a clinical prediction model. Cancer Med. 2023;12(12):13031\u201340.","journal-title":"Cancer Med"},{"issue":"40","key":"3723_CR14","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.2217\/fon-2022-0337","volume":"18","author":"P Yu","year":"2022","unstructured":"Yu P, Zhu S, Pu Y, et al. Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer. Future Oncol. 2022;18(40):4483\u201392.","journal-title":"Future Oncol"},{"issue":"3","key":"3723_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10120-018-0895-x","volume":"22","author":"X Cheng","year":"2019","unstructured":"Cheng X, Yu S, Wang Y, et al. The role of oxaliplatin in the adjuvant setting of different Lauren\u2019s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer. 2019;22(3):587\u201397.","journal-title":"Gastric Cancer"},{"issue":"9813","key":"3723_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321.","journal-title":"Lancet"},{"key":"3723_CR17","doi-asserted-by":"publisher","first-page":"861777","DOI":"10.3389\/fmed.2022.861777","volume":"9","author":"L Su","year":"2022","unstructured":"Su L, Zhao S, Yin Y, et al. POF (paclitaxel\/oxaliplatin\/5-fluorouracil\/leucovorin) vs. SOX\/CAPOX\/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: study protocol for a randomized controlled trial, FNF-014 trial. Front Med (Lausanne). 2022;9:861777.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3723_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10637-017-0506-4","volume":"36","author":"M Shi","year":"2018","unstructured":"Shi M, Sun J, Zhou J, et al. Phase I dose escalation and Pharmacokinetic study on the nanoparticle formulation of polymeric micellar Paclitaxel for injection in patients with advanced solid malignancies. Invest New Drugs. 2018;36(2):269\u201377.","journal-title":"Invest New Drugs"},{"issue":"10","key":"3723_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2217\/nnm-2023-0080","volume":"18","author":"X Deng","year":"2023","unstructured":"Deng X, Huang X, Dong X, et al. Efficacy and safety of nanopaclitaxel formulation for cancer treatment: evidence from randomized clinical trials. Nanomed (Lond). 2023;18(10):833\u201343.","journal-title":"Nanomed (Lond)"},{"issue":"2","key":"3723_CR20","doi-asserted-by":"publisher","first-page":"e232303","DOI":"10.1148\/radiol.232303","volume":"312","author":"M Nanaa","year":"2024","unstructured":"Nanaa M, Gupta VO, Hickman SE, et al. Accuracy of an artificial intelligence system for interval breast Cancer detection at screening mammography. Radiology. 2024;312(2):e232303.","journal-title":"Radiology"},{"issue":"4","key":"3723_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/03008916241231035","volume":"110","author":"F Tucci","year":"2024","unstructured":"Tucci F, Laurinavicius A, Kather JN, et al. The digital revolution in pathology: towards a smarter approach to research and treatment. Tumori. 2024;110(4):241\u201351.","journal-title":"Tumori"},{"key":"3723_CR22","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2. 2023.\/https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric"},{"issue":"2","key":"3723_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00432-014-1816-y","volume":"141","author":"E Kaytan Saglam","year":"2015","unstructured":"Kaytan Saglam E, Yucel S, Balik E, et al. Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study. J Cancer Res Clin Oncol. 2015;141(2):361\u20137.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"33","key":"3723_CR24","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387\u201393.","journal-title":"J Clin Oncol"},{"key":"3723_CR25","doi-asserted-by":"crossref","unstructured":"Takahari D, Hamaguchi T, Yoshimura K et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011:67(6).","DOI":"10.1007\/s00280-010-1432-8"},{"issue":"7","key":"3723_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3723_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141\u20138.","journal-title":"Ann Oncol"},{"key":"3723_CR28","doi-asserted-by":"crossref","unstructured":"Zhao S, Lin R, Fan NF et al. Final survival results from a multicenter, randomized phase II trial of intravenous Paclitaxel plus FOLFOX (ivPOF) and\/or intraperitoneal Paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT\/FNF 004. J Clin Oncol. 2021;39:4041.","DOI":"10.1200\/JCO.2021.39.15_suppl.4041"},{"key":"3723_CR29","doi-asserted-by":"crossref","unstructured":"Lin R, Chen Y, Zhu J et al. POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal Paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): update from a multicenter, randomized phase II trial, FNF-004 trial. J Clin Oncol. 2019;37:403.","DOI":"10.1200\/JCO.2019.37.15_suppl.4035"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03723-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:01:13Z","timestamp":1741327273000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03723-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3723"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03723-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethical Committee of Jiangsu Cancer Hospital approved the study, which adhered to the 1964 Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}